Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

By Rene Pretorius

June 2, 2025

The GLP-1 drug market, vital for diabetes and obesity treatments, is undergoing a seismic shift—most notably Novo Nordisk GLP-1 market share loss to rising competitors like Eli Lilly. This article unpacks the key forces and feedback loops behind Novo Nordisk GLP-1 market share loss in the booming GLP-1 sector. By examining how misjudged demand forecasts opened the door for rival expansion, we offer actionable insights to help pharma leaders recalibrate strategy and stay competitive in a rapidly evolving therapeutic space.

Background: The GLP-1 Arena

GLP-1 drugs, originally for type 2 diabetes, are now obesity game-changers, with the market eyed to top $100 billion by 2030. Novo Nordisk led with Ozempic (diabetes) and Wegovy (obesity), holding a 69% global share in Q2 2024. But Eli Lilly’s Mounjaro and Zepbound (both tirzepatide-based) are closing in fast, posting $3.01 billion in Q2 2024 sales with explosive growth (215.5% YoY for Mounjaro, 140% quarterly for Zepbound).

Key Drivers and Feedback

Here’s a clear breakdown of what’s fueling Novo Nordisk GLP-1 market share loss and how competitors capitalized.

1. Misjudging Demand

  • What Happened: Novo Nordisk underestimated the skyrocketing demand for GLP-1 drugs, especially for weight loss. Wegovy sales hit $2.6 billion in Q1 2025 (up 85% YoY) but dropped 13% from Q4 2024 due to supply shortages.
  • Impact: Stockouts left patients and doctors frustrated, with Wegovy on the FDA shortage list into late 2024, pushing customers away.
  • Feedback: Supply Crunch Cycle
    • Short supply → Limited access → Unhappy patients → Switch to rivals like Zepbound → Shrinking market share → Rush to boost production → Delays in scaling up → Ongoing shortages.
    • Takeaway: This cycle turned a planning misstep into a lasting hit to Novo’s position.

2. Rivals Seize the Opening

  • What Happened: Eli Lilly jumped on Novo’s supply woes, ramping up Mounjaro and Zepbound output and marketing. Zepbound hit blockbuster status in Q2 2024, with 140% quarterly growth.
  • Impact: Lilly’s tirzepatide outperformed, cutting weight by up to 21% versus Wegovy’s 15%. Smart moves like lower-priced Zepbound vials and direct-to-consumer sales pulled share from Novo.
  • Feedback: Competitor Surge
    • Novo’s shortages → Lilly’s ready stock → Wider reach for Lilly → Stronger buzz and trust → More prescriptions for Mounjaro/Zepbound → Novo loses ground → Lilly invests more in growth → Bigger lead.
    • Takeaway: Lilly turned Novo’s gap into a springboard for dominance.

3. Edge in Innovation

  • What Happened: Lilly’s tirzepatide delivered better weight loss (up to 27% over 84 weeks vs. semaglutide’s 15% over 68 weeks). Their oral GLP-1, orforglipron, also promises ease, showing 7.9% loss in 40 weeks.
  • Impact: Doctors and patients leaned toward Lilly, with analysts at BMO Capital Markets in 2025 calling Lilly’s portfolio “superior,” downgrading Novo’s stock.
  • Feedback: Innovation Push
    • Novo’s early lead → Lilly’s R&D step-up → Better results from Lilly → Prescriptions shift → Novo races to innovate (e.g., CagriSema) → Setbacks (22.7% weight loss vs. 25% hoped) → Lilly holds edge.
    • Takeaway: Novo’s innovation lag let Lilly reset the competitive bar.

4. Market Pressures Pile On

  • What Happened: Obesity rates (138 million in the U.S.) and new uses (e.g., Zepbound for sleep apnea) spike demand. New players like Roche, Pfizer, and Amgen, plus compounding pharmacies, crowd in. Novo cuts Wegovy prices and partners with CVS to fight back.
  • Impact: Price wars and knockoffs squeeze profits, with 10-15% annual price drops expected by 2027 as rivals chase coverage and access.
  • Feedback: Competition Squeeze
    • New rivals and copies → Price cuts → Thinner margins for Novo → Less cash for R&D and marketing → Weaker stance → More gains for others → Rising competition.
    • Takeaway: Broader pressure turned Novo’s misstep into a market-wide challenge.

Dynamic Insights

These feedback loops—supply crunches, competitor surges, innovation gaps, and market pressures—show how Novo Nordisk’s demand miscalculation handed rivals, especially Lilly, a clear opening. Lilly’s momentum could push its share to 44% by 2031, with Novo at 36%. Modeling tools can map this, tracking supply, prescriptions, and rival moves to forecast outcomes. Novo’s $4.1 billion U.S. plant bet aims to catch up (together with expanding market access models). But delays could widen Lilly’s lead.

Action Steps for Pharma Leaders

  1. Sharpen Demand Forecasts: Use advanced analytics to nail demand, dodging supply pitfalls rivals exploit.
  2. Boost Capacity Fast: Scale production quickly (e.g., Novo’s $16.5 billion Catalent buy and Lilly’s $5.3 billion Indiana push to meet need).
  3. Drive Breakthroughs: Pour resources into next-gen drugs (e.g., oral options) and new uses to stay ahead.
  4. Lock In Position: Balance pricing and partnerships (like Novo’s CVS move) to hold share amid price wars.
  5. Track the System: Leverage dynamic modeling to spot trends and adjust strategies on the fly.

Bottom Line

Novo Nordisk GLP-1 market share slipped when it misjudged demand. It created an opening for Eli Lilly and others to surge ahead with better supply, stronger results, and bold moves. This flags the need for dynamic forecasting, fast scaling, and relentless innovation to win in a crowded, high-stakes market.

Reference url

Recent Posts

BioNTech BMS collaboration
   

BioNTech BMS Collaboration: Pioneering Advances in Solid Tumor Treatment with BNT327

🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?

Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.

Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!

#SyenzaNews #oncology #drugdevelopment #MarketAccess

Pluvicto prostate cancer trial
        

Pluvicto Prostate Cancer Trial: Phase III Results

🔍 Have you heard about the latest breakthrough in prostate cancer treatment?

Novartis’s Pluvicto™ has shown significant clinical benefits in earlier-stage prostate cancer, highlighting its potential to transform treatment paradigms for patients with metastatic hormone-sensitive prostate cancer. With promising data on radiographic progression-free survival, the implications for healthcare systems are profound, pushing us toward more effective and targeted therapies for this pressing health challenge.

Dive into the full article to explore how Pluvicto™ is shifting the landscape of prostate cancer management!

#SyenzaNews #oncology #HealthcareInnovation

Novo Nordisk performance
      

Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.

A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.

#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.